Vanda Pharmaceuticals (VNDA) Q2 2024 earnings summary

Executive summary

• Achieved FDA approval for Fanapt in bipolar I disorder, expanding commercial potential and psychiatry portfolio focus.

• Tripled sales force size and expanded prescriber engagement programs to support Fanapt and Ponvory launches.

• Initiated commercial and patient support activities for Ponvory in multiple sclerosis, with plans for expansion into psoriasis and ulcerative colitis.

• HETLIOZ continues to face revenue erosion from generics in the U.S., but maintains significant market share and is expanding in Europe.

• The company is advancing late-stage and early-stage pipeline programs, including tradipitant, milsaperidone, and VPO-227.

Financial highlights

• Q2 2024 total revenues were $50.5M, up 10% year-over-year and 6% sequentially.

• Net loss for Q2 2024 was $4.5M, compared to net income of $1.5M in Q2 2023.

• Fanapt Q2 2024 sales were $23.2M (down 4% YoY, up 12% sequentially); HETLIOZ $18.7M (down 15% YoY, down 7% sequentially); Ponvory $8.6M (up 26% sequentially).

• First half 2024 total revenues were $97.9M, down 10% YoY; net loss was $8.7M versus net income of $4.8M in 2023.

• Cash and equivalents at June 30, 2024, were $387.7M, down $0.6M from year-end 2023.

Outlook and guidance

• Reinstated 2024 guidance: total net product sales expected between $180M and $210M; year-end cash between $360M and $390M.

• Full commercial infrastructure for Fanapt and Ponvory expected by year-end, with revenue impact anticipated later in 2024.

• HETLIOZ sales expected to decline further due to ongoing generic competition.

• Tradipitant NDA for gastroparesis under FDA review, PDUFA date September 18, 2024; motion sickness NDA submission expected Q4 2024.

• Milsaperidone NDA submission for schizophrenia and bipolar I disorder planned for early 2025.